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In recent years a number of immunotherapeutical strategies have
been developed for the treatment of solid tumours and metastatic
disease. Bispecific antibodies (BsMAb) that cross-link the CD3/T-
cell receptor (TcR) complex on T lymphocytes and tumour-associ-
ated antigens have been shown to effectively redirect the cytolytic
activity of CTLs to tumour cells (de Gast et al, 1995; Demanet et
al, 1996; Renner et al, 1996). In our laboratory we developed BIS-
1 BsMAb which is able to cross-link the CD3/TcR complex on
CTLs and the tumour-associated antigen EGP-2 on carcinoma
cells (de Leij et al, 1994). Intraperitoneal injection of in vitro acti-
vated, BIS-1 IgG-coated autologous T-cells into patients with
malignant ascites or pleural exudates caused a significant anti-
tumour effect and a strong local inflammatory reaction (Kroesen et
al, 1993). In a phase I/II trial, intravenous administration of BIS-1
F(ab¢)2 to renal cell carcinoma patients with disseminated disease
during standard subcutaneous (s.c.). IL-2 treatment also induced
immune cell activation (Kroesen et al, 1994). There was, however,
no evidence that BIS-1-coated lymphocytes distributed into
tumour tissue, and so far no notable anti-tumour responses have
been observed (Nieken et al, unpublished observations).
One important observation in clinical studies of systemic
administration of CD3 directed BsMAbs in general, and BIS-1
F(ab¢)2 in specific, for the treatment of metastatic disease is the
strong lymphopenia starting as early as 30 min after initiation of
BsMAb infusion (de Gast et al, 1995; Janssen et al, 1995). Success
of BsMAb therapy is dependent on the contact between immune
effector cells and tumour cells. It is therefore important to under-
stand the cause(s) of lymphocyte disappearance from the periph-
eral blood upon BIS-1 F(ab¢)2 infusion and the lack of distribution
into the tumour tissue. Understanding the underlying mecha-
nism(s) may lead to new strategies that can selectively target CTLs
to the tumour tissue and improve therapeutic outcome (Molema et
al, 1997, 1998b). Possibly, the lymphopenia observed during intra-
venous (i.v.) BIS-1 F(ab¢)2 administration is the result of a
(temporary) increased adhesiveness of lymphocytes to the blood
vessel walls. Subsequently, lymphocytes can extravasate, migrate
into organ parenchyma and re-appear in the circulation via the
lymphatic system. The present study describes the effects of
binding of CD3- versus CD5-directed BsMAbs to peripheral blood
mononuclear cells (PBMC) on interactions between PBMC and
resting endothelial cell monolayers, the latter representing the
status of the majority of endothelial cells in the body. Important for
the interactions between leucocytes and endothelial cells (Figure
1) are the cell adhesion molecules sialyl Lewisx/E- and L-selectin,
VLA-4/VCAM-1 and LFA-1/ICAM-1 (Springer, 1994). We there-
fore also studied the expression of these cell adhesion molecules
on PBMC after binding of BsMAb, and on endothelium during
adhesion/transendothelial migration of BsMAb-coated PBMC.
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Summary Bispecific antibody (BsMAb) BIS-1 has been developed to redirect the cytolytic activity of cytotoxic T lymphocytes (CTL) to
epithelial glycoprotein-2 (EGP-2) expressing tumour cells. Intravenous administration of BIS-1 F(ab¢)2 to carcinoma patients in a phase I/II
clinical trial, caused immunomodulation as demonstrated by a rapid lymphopenia prior to a rise in plasma tumour necrosis factor-a and
interferon-g levels. Yet, no lymphocyte accumulation in the tumour tissue and no anti-tumour effect could be observed. These data suggest a
BsMAb-induced lymphocyte adhesion to blood vessel walls and/or generalized redistribution of the lymphocytes into tissues. In this study, we
describe the effects of BIS-1 F(ab¢)2 binding to peripheral blood mononuclear cells (PBMC) on their capacity to interact with resting endothelial
cells in vitro. Resting and pre-activated PBMC exhibited a significant increase in adhesive interaction with endothelial cells when preincubated
with BIS-1 F(ab¢)2, followed by an increase in transendothelial migration (tem). Binding of BIS-1 F(ab¢)2 to PBMC affected the expression of a
number of adhesion molecules involved in lymphocyte adhesion/migration. Furthermore, PBMC preincubated with BIS-1 F(ab¢)2 induced the
expression of endothelial cell adhesion molecules E-selectin, VCAM-1 and ICAM-1 during adhesion/tem. These phenomena were related to
the CD3 recognizing antibody fragment of the BsMAb and dependent on lymphocyte–endothelial cell contact. Possibly, in patients, the BIS-1
F(ab¢)2 infusion induced lymphopenia is a result of generalized activation of endothelial cells, leading to the formation of a temporary sink for
lymphocytes. This process may distract the lymphocytes from homing to the tumour cells, and hence prevent the occurrence of BIS-1 F(ab¢)2
– CTL-mediated tumour cell lysis. © 2000 Cancer Research Campaign
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Monoclonal antibodies
Primary monoclonal antibodies used in this study are summarized
in Table 1. Fluorescein isothiocyanate (FITC)- labelled rabbit anti-
mouse Ig F(ab¢)2 was obtained from Dako A/S (Glostrup,
Denmark).
Bispecific antibodies
Characteristics of the BsMAbs BIS-1 F(ab¢)2 (Kroesen et al, 1994),
BIS-18 IgG (Kroesen et al, 1995) and SHR-1 IgG (Clark et al,
1989) used in this study are given in Table 2. SHR-1 was a kind
gift of Dr M Clark, Cambridge, UK. Solutions of the BsMAbs
used in the described assays were tested negative for lipopoly-
saccharide using the Limulus assay (Nodia/Chromogenics, Leiden,
The Netherlands).
Cells
PBMC
Human PBMC were obtained from heparinized blood by density
centrifugation on Lymphoprep (Nycomed, Oslo, Norway). After
washing, PBMC were resuspended in RPMI-1640 supplemented
with 2% heat inactivated pooled human serum, 2 mM glutamine
and 60 mg ml–1 gentamycin (hereafter referred to as RPMI com-
plete medium). PBMC kept overnight in RPMI complete medium
were considered resting. PDB activation was achieved by
culturing PBMC for 24 h at 5 ng ml–1 phorbol 12,13-dibutyrate
(PDB; Sigma Chemical Co., Zwijndrecht, The Netherlands) in
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Figure 1 Lymphocyte–endothelial cell interactions leading to lymphocyte extravasation into tissue. Tethering of the lymphocytes (1) is accomplished by
interactions between selectin molecules on both lymphocytes and endothelial cells and their sialyl Lewisx (sLex) ligands. This is followed by firm adhesion and
lymphocyte activation (2), and transendothelial migration (3). Adhesion, activation and migration are mediated by integrins VLA-4 and LFA-1 on lymphocytes, and
their respective counterstructures VCAM-1 and ICAM-1 (both Immunoglobulin SuperFamily (IgSF) members), expressed on the endothelium. After transendothelial
migration lymphocytes move into the tissue mediated by concerted actions of soluble factors such as chemoattractants, and integrins, among others
Table 1 Summary of antibodies used for flow cytometric analysis of cell
adhesion molecule expression
Antibody Antigen recognized Source
name
Anti-CD15s CD15s, sialyl Lewisx Pharmingen, San Diego, CA, USA
Leu8 L-selectin Becton Dickinson, San Jose,
CA, USA
HP2/1 VLA-4 Dr M Sánchez-Madrid,
Madrid, Spain
NKI.L16 LFA-1, high affinity Dr Y van Kooyk, Nijmegen, The
variant Netherlands
NKI.L15 LFA-1, total Dr Y van Kooyk, Nijmegen, The
Netherlands
anti-CD31 CD31 (PECAM-1) Dako A/S, Glostrup,
Denmark
24–31 (FITC) CD40-L Dr A Kashran, Leuven,
Belgium
H18/7 E-selectin Dr MA Gimbrone Jr,
Boston, MA, USA
E1/6 VCAM-1 Dr MA Gimbrone Jr
Hu5/3 ICAM-1 Dr MA Gimbrone Jr
Anti-CD3 (PE) CD3 Southern Biotechn. Assoc.,
Birmingham, AL, USA
Anti-CD4 (FITC) CD4 Immuno Quality Products,
Groningen, The Netherlands
Anti-CD8 (PE) CD8 Immuno Quality Products
1A29 rat ICAM-1 Dr Miyasaka, Osaka, Japan474 G Molema et al
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RPMI complete medium (Oppenheimer-Marks et al, 1991).
Interleukin (IL)-2 activated PBMC were cultured in the presence
of 100 IU ml–1 rec. huIL-2 (EuroCetus, Amsterdam, The
Netherlands) for 5 days, during which the medium was refreshed
after 3 days. Anti-CD3/IL-2-activated PBMC were obtained by
culturing the cells in the presence of the mitogenic anti-CD3 MAb
WT32 (Tax et al, 1983) for 3 days, washing and culturing for an
additional 2 days in complete medium supplemented with 100 IU
ml–1 rec. huIL-2. All PBMC populations were cultured at 37°C in a
humidified atmosphere containing 5% carbon dioxide.
Phenotyping of the PBMC populations showed that resting,
PDB and IL-2-activated lymphocytes consisted of more than 75%,
and anti-CD3/IL-2-activated lymphocytes of more than 98% CD3-
positive T lymphocytes. These percentages as well as the
CD4/CD8 ratio differed significantly between different donors
(data not shown).
Endothelial cells
Human umbilical vein endothelial cells (HUVEC) were isolated
and cultured in the presence of 20% human serum and supple-
ments as described by Mulder et al (1994). By routine flow cyto-
metric phenotyping for CD31 the cells were found to be uniformly
positive. HUVEC passages 2–4 were used for the studies
presented.
Determination of lymphocyte adhesion/transendothelial
migration
Experiments to investigate the effects of BsMAb binding to
PBMC on interactions with endothelium were performed as
described (Molema et al, 1998a). Briefly, HUVEC were seeded on
Vitrogen 100 collagen layers (Collagen Corporation, Palo Alto,
CA, USA) at confluent cell density and cultured for 48 h.
Precoating of PBMC with BsMAbs was performed for 45 min at
RT at 1 mg ml–1 BsMAb in RPMI complete medium, whereas
uncoated PBMC were incubated in RPMI complete medium only.
After extensive washing, both uncoated and BsMAb-coated
PBMC were resuspended at 5–73105 cells ml–1 in RPMI complete
medium. The adhesion/tem assay was started by applying 500 ml
PBMC suspension per well. After incubation at 37°C, 5% carbon
dioxide in a humidified atmosphere for 3 h, non-adherent PBMC
were removed by extensive washing, adherent cells were detached
by 0.05% trypsin/0.5 mM EDTA (ICN Biomedicals B.V.,
Zoetermeer, The Netherlands) treatment, and migrated cells by
treatment with collagenase (2 mg ml–1 in PBS, freshly prepared;
collagenase was a kind gift of Knoll A/G, Ludwigshafen,
Germany). Alternatively, HUVEC were cultured in the presence of
20% fetal calf serum (Biowhitaker, Brussels, Belgium). Under
these conditions the adhesion/tem assays were performed using
HUVEC cultured on gelatin-coated wells, an experimental setup
frequently applied by others (Masinovsky et al, 1990; Thornhill et
al, 1990). In this setup, adherent/migrated cells were released by
incubation of the wells with trypsin/EDTA, and analysis of the
total number of adherent plus migrated PBMC was performed.
Results from both assays were comparable with respect to absolute
numbers of adherent plus migrated PBMC and the effects of the
BsMAbs. Adhesion/tem results shown are obtained with HUVEC
cultured on collagen gels unless otherwise stated.
Flow cytometric determination of absolute cell numbers was
performed using fluorosphere reagent (Immuno Check EPICS
alignment fluorospheres or Flow Count fluorospheres from Coulter
Corp., Hialeah, FL, USA) as described (Molema et al, 1998a).
Flow cytometric analysis of adhesion molecule
expression by PBMC and HUVEC
All incubations and wash steps were performed at 4°C. Cells were
incubated with primary antibodies in phosphate-buffered saline
(PBS) supplemented with 5% human pooled serum. When using
anti-LFA-1 antibody NKI-L16 (Van Kooyk et al, 1991), all incuba-
tions were performed in Ca2+/Mg2+ free HBSS buffer (Gibco-
BRL/Life Technologies). In the case of indirect fluorescence
staining, detection was performed with FITC-labelled rabbit anti-
mouse Ig F(ab¢)2. Flow cytometric analysis was performed on a
Coulter Elite Cytometer (Coulter Electronics, Hialeah, FL, USA).
Ten thousand (PBMC) and 2000 (HUVEC) events were recorded
and analysed with Winlist (V3.1) from Verity Software House,
ME, USA.
Statistical analysis
The effect of BsMAb binding to PBMC on PBMC adhesion and
transendothelial migration was analysed statistically using the
two-sided Student’s t-test for unpaired samples with different stan-
dard deviation (s.d.) P-values of < 0.05 were considered to be
significant at 95% confidence intervals.
RESULTS
Effect of PBMC activation status on adhesion/tem
The effects of PBMC activation on their subsequent interaction
with resting HUVEC is shown in Figure 2. Resting PBMC exhib-
ited low adhesive and migratory capacity. Activation of the PBMC
with either IL-2 or PDB led to a three-to fourfold increase in both
adhesion and tem. Anti-CD3/IL-2 activation of PBMC led to a
Table 2 Characteristics of the bispecific antibodies (BsMAb) used in this study
BsMAb BsMAb Therapeutic use T-cell recognition Tumour cell recognition
format Antigen Antibody Antibody Antigen Antibody Antibody
name isotype name isotype
BIS-1 F(ab¢)2 Renal cell carcinoma CD3 RIV-9 Mouse IgG3 EGP-2 MOC31 Mouse IgG1
BIS-18 IgG (Not used) CD5 83-P2E6 Mouse IgG2b EGP-2 MOC31 Mouse IgG1
SHR-1 IgG Non-Hodgkin’s lymphoma CD3 YTH12.5 Rat IgG2b CD19 MG1CD19 Mouse IgG1sevenfold increase in lymphocyte adherence compared to resting
PBMC. In contrast to the other activation routes, activation with
anti-CD3/IL-2 equipped the PBMC with an enhanced migratory
capacity as well.
Effect of BsMAb binding to PBMC on PBMC
adhesion/tem
Effect on PBMC adhesion
In all PBMC populations studied, binding of BIS-1 F(ab¢)2 to the
cells significantly affected PBMC–endothelial cell interactions
(Figure 2), albeit to a different extent. An irrelevant BsMAb, BIS-
100 (anti-rat CD3/TcR ´ anti-EGP-2) did not affect adhesion and
migration of PBMC (data not shown). The anti-CD5 directed
BsMAb BIS-18 induced a slight (1.3- to 1.4-fold) increase in adhe-
sion in all PBMC populations studied. These latter increases were,
however, statistically not significant except for the effect on the
adhesion of anti-CD3/IL-2 activated PBMC (P = 0.01).
Effect on PBMC migration
For all PBMC populations except the PDB activated cells, tem of
BIS-1 F(ab¢)2 pre-incubated cells was significantly increased
(Figure 2). The absolute numbers of migrated cells in these popu-
lations differed notably, possibly reflecting the differences in
intrinsic migratory capacity of the various PBMC populations.
Binding of BIS-18 did not exert an effect on the migration of the
PBMC populations studied (Figure 2).
In different experiments, when using different PBMC and
HUVEC isolates, the absolute numbers of adherent and migrated
cells varied significantly between experiments. In all experiments,
however, we observed similar increases in adhesion/tem of PBMC
pre-incubated with BIS-1 F(ab¢)2, but not BIS-18, as described
above. The data presented are therefore representative of other
experiments.
Effect of BsMAb binding to PBMC on lymphocyte
adhesion molecule expression
The increased in vitro adhesion/migration characteristics of resting
PBMC preincubated with BIS-1 F(ab¢)2 led us to determine the
effect of BIS-1 F(ab¢)2 and BIS-18 binding to PBMC on the
expression of lymphocyte adhesion molecules now believed to
play an important role in adhesion/tem. Most notably were the
increased expression of CD15s and CD31, and decreased expres-
sion of L-selectin on PBMC preincubated with BIS-1 F(ab¢)2
(Figure 3). BIS-18 binding to PBMC did not affect these particular
adhesion molecules. Both BIS-1 F(ab¢)2 and BIS-18 induced a rise
in the expression of VLA-4 and high affinity LFA-1 (L16 epitope),
whereas total LFA-1 (L15 epitope) expression slightly changed.
This suggests that both BIS-1 F(ab¢)2 and BIS-18 binding under the
conditions used were able to activate PBMC, but to a different
extent.
Adhesion molecule expression of HUVEC after PBMC
adhesion/tem
We next determined whether the adhesion molecule expression of
HUVEC changed during the actual adhesion/tem process of
resting PBMC preincubated with BIS-1 F(ab¢)2. Figure 4 shows
that the expression of especially E-selectin and VCAM-1
CD3 bispecific antibody induce PBMC–endothelial cell interactions 475
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Figure 2 Effect of PBMC activation status and BsMAb binding on PBMC adhesion/tem to/through monolayers of resting HUVEC. PBMC were activated as
described in Materials and Methods. After pre-incubation of PBMC at RT for 45 min with 1 mg ml–1 of either BIS-1F (ab¢)2 or BIS-18, cells were subjected to the
adhesion/tem assay. Open bars represent adherent, hatched bars migrated PBMC. Note the difference in scale in D as compared to A, B and C. Values are
means ± s.d. of triplicate experiments. Statistically significant increases in adhesion or migration compared to PBMC not pre-incubated with BsMAb: * P < 0.02,
** 0.02 < P < 0.05markedly increased during the 3-h period in which the
adhesion/tem of BIS-1 F(ab¢)2-coated PBMC took place, whereas
ICAM-1 expression only moderately increased. No changes were
observed after adhesion/tem of resting PBMC or PBMC preincu-
bated with BIS-18 (data not shown). From this it was concluded
that resting PBMC coated with BIS-1 F(ab¢)2 were able to activate
HUVEC to express adhesion molecules during PBMC
adhesion/tem.
Involvement of soluble factors in BsMAb induced
lymphocyte adhesion/tem
Tumour necrosis factor a (TNF-a) is a potent mediator of endo-
thelial cell activation. We therefore investigated whether TNF
release during the adhesion/tem of resting PBMC coated with BIS-
1 F(ab¢)2 could be a cause of HUVEC activation. Supernatants of
adhesion/tem assays were analysed in a bioassay using TNF-a-
sensitive WEHI-164 cells (Morgan et al, 1991). Within the assay’s
concentration range of 1–32 pg ml–1, no biologically active TNF-a
could be detected (data not shown). We next performed
adhesion/tem assays with BIS-1 F(ab¢)2-coated PBMC in the pres-
ence of 50 mg ml–1 (0.3 mM) neutralizing anti-TNF-a antibody
(MAb 61E71 (Leeuwenberg et al, 1988), kindly provided by Dr
WA Buurman, Maastricht, The Netherlands). We hypothesized that
by means of this, minute amounts of this cytokine that might have
been produced locally at pharmacologically active concentrations
enabling HUVEC activation, would be inactivated. The number of
adherent/migrated cells did, however, not change in the presence of
either anti-TNF-a or control antibody (data not shown). Also, no
expression of transmembrane bound TNF-a, a possible mechanism
by which the BIS-1 F(ab¢)2-coated lymphocytes could activate the
endothelial cells during adhesion/tem without the release of soluble
TNF-a (Lou et al, 1996), could be detected by FACS using PE-
labelled anti-TNF-a (clone B-C7, kindly provided by Immuno
Quality Products, Groningen, The Netherlands; data not shown).
Subsequently, we investigated whether any soluble factor
released during the adhesion/tem assay could be the cause of the
observed endothelial cell activation. Therefore, cell free medium
harvested after the 3-h adhesion/tem assay was transferred to new,
resting HUVEC monolayers. After 3 h incubation, HUVEC were
phenotyped for the expression of E-selectin, VCAM-1 and ICAM-
1. As can be seen from Figure 5, E-selectin did not become
expressed when HUVEC were exposed to cell free medium of
adhesion/tem assays of BIS-1 F(ab¢)2-coated PBMC. Similarly, no
increase in VCAM-1 or ICAM-1 expression could be detected
upon transferral and incubation of resting HUVEC with the cell
free media (data not shown). Taken together, these data indicate
that the observed endothelial cell activation was a result of direct
contact between BIS-1 F(ab¢)2-coated PBMC and HUVEC.
Effect of SHR-1 BsMAb on PBMC adhesion/tem
SHR-1 is a BsMAb developed for the treatment of CD19-positive
tumours such as non-Hodgkin’s lymphoma. SHR-1 consists of a
CD3 recognizing fragment, like BIS-1 F(ab¢)2, and a CD19 recog-
nizing fragment. After i.v. administration to patients with non-
Hodgkin’s lymphoma, SHR-1 also induced a rapid and transient
lymphopenia (de Gast et al, 1995). To determine whether the
effects observed with BIS-1 F(ab¢)2 were a BIS-1-specific or a
more generalized phenomenon of CD3-directed BsMAbs, we
studied the effects of SHR-1 binding to PBMC on PBMC–endo-
thelial cell interactions. Under similar conditions as used with
BIS-1 F(ab¢)2, SHR-1 binding to PBMC also resulted in an
increased PBMC adhesion/tem (Figure 6). The effect of SHR-1
could be titrated down from a 6.7-fold increase in adhesion/tem
after preincubation of resting PBMC at 1.0 mg ml–1 SHR-1, to a
4.9-fold increase at 0.1 mg ml–1, and a 2.3-fold increase at 
0.01 mg ml–1. Similarly, the effect of BIS-1 F(ab¢)2 could be titrated
down to a 3.8-fold increase in adhesion/tem of resting PBMC
incubated at 0.1 mg ml–1 BIS-1 F(ab¢)2 and a 2.7-fold increase after
476 G Molema et al
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Figure 3 Effect of BIS-1 F(ab¢)2 and BIS-18 binding to resting PBMC on the
expression of lymphocyte cell surface markers as measured by flow
cytometry. Open bars: PBMC; closed bars: PBMC preincubated with BIS-1
F(ab¢)2; hatched bars: PBMC preincubated with BIS-18. Both BsMAbs were
present for 45 min at RT at 1.0 mg ml–1 as described in Materials and
Methods. For those antibodies used in an indirect immunofluorescence
protocol, the mean fluorescence intensities were corrected for the signal
obtained with the control antibody 1A29
Figure 4 Adhesion molecule expression of HUVEC as measured by flow
cytometry after being exposed for 3 h to interactions with either resting
PBMC (dotted line) or resting PBMC pre-incubated with BIS-1 F(ab¢)2 (solid
line). For clarity, irrelevant antibody staining (MAb 1A29, MFI < 10), and
expression of adhesion molecules by HUVEC that were not exposed to
PBMC (identical to the expression by HUVEC exposed to PBMC) are not
shownincubation at 0.01 mg ml–1. Phenotyping of HUVEC after facili-
tating SHR-1-coated PBMC adhesion/tem also revealed an
increased expression of E-selectin, VCAM-1 and ICAM-1, and
transferral of cell free assay medium, as described above, did not
activate the HUVEC (data not shown). From these data, it is
concluded that the effects of BIS-1 F(ab¢)2 binding to PBMC on
PBMC–endothelial cell interactions are not restricted to the
BsMAb BIS-1 F(ab¢)2 developed in our laboratory, but may well
be a general characteristic of anti-CD3 fragment containing
BsMAbs.
DISCUSSION
The rapid and transient disappearance of lymphocytes from the
peripheral blood of carcinoma patients upon i.v. BIS-1 F(ab¢)2
administration is at present not well understood. Possibly, the
observed lymphopenia results from temporary lymphocyte
margination. Eventually, increased margination may be followed
by lymphocyte extravasation into organs and/or tumour tissue.
Although CTLs need to leave the systemic circulation to become
effective in solid tumour cell killing, for maximal anti-tumour
effects an optimal redistribution of BIS-1 F(ab¢)2-coated CTLs to
the tumour tissue is a prerequisite, and a generalized lymphocyte
redistribution undesirable. For a lymphopenia to occur, the inter-
action between the lymphocytes and endothelial cells (of which
the resting phenotype represents the majority of endothelial cells
in the body) plays a central role. In this study, we investigated the
effects of BIS-1 F(ab¢)2 binding to PBMC on generally accepted
processes in leucocyte adhesion/tem, i.e. the expression of cell
adhesion molecules and soluble factors leading to cell activation.
We showed that BIS-1 F(ab¢)2 binding to resting PBMC resulted in
increased PBMC–endothelial cell interactions. During the interac-
tion between BIS-1 F(ab¢)2-coated PBMC and endothelial cells,
the HUVEC became activated to express E-selectin and VCAM-1.
This effect was most likely due to a direct interaction between the
PBMC and the HUVEC, as soluble mediator(s) could not be
demonstrated to be present in the assay medium. These effects
were not BIS-1 F(ab¢)2-specific: the BsMAb SHR-1, developed for
the treatment of CD19-positive tumours, exerted similar effects.
Most likely, the increased PBMC–endothelial cell interactions
were a CD3 binding related phenomenon, since the CD5-directed
BsMAb BIS-18 did not affect PBMC adhesion/tem. Both antibody
fragments present in BIS-1 F(ab¢)2 and SHR-1 recognize the
epsilon chain of CD3, which is a signal transducing molecule.
CD5, recognized by BIS-18, does however also lead to signal
transduction in lymphocytes. Moreover, once the TcR/CD3
complex is engaged in signal transduction, the cytoplasmic
domain of CD5 becomes rapidly phosphorylated, as are the TcR z
chains (Gringhuis et al, 1998a, 1998b). The molecular basis for the
observed differences of BIS-1 versus BIS-18 mediated effects on
lymphocyte–endothelial cell interaction needs to be investigated
further. In addition to the effects observed with BIS-1 F(ab¢)2, we
found that binding of the parental CD3 recognizing MAb RIV9
induced PBMC adhesion/tem to a similar extent as BIS-1 F(ab¢)2
(unpublished data). Other CD3-directed MAbs also affected
CD3 bispecific antibody induce PBMC–endothelial cell interactions 477
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Figure 5(A) Flow cytometric analysis of E-selectin expression by HUVEC after facilitating adhesion/tem of resting PBMC or resting PBMC preincubated with
either 1 mg ml–1 BIS-1 F(ab¢)2 or BIS-18. (B) Flow cytometric analysis of E-selectin expression by HUVEC after 3 h exposure to cell free medium retrieved from
adhesion/tem assays performed with resting PBMC or resting PBMC preincubated with either 1 mg ml–1 BIS-1 F(ab¢)2 or BIS-18
Figure 6 Effect of SHR-1 binding to resting PBMC on adhesion/tem
to/through resting HUVEC cultured on gelatin-coated wells as described in
Materials and Methods. After pre-incubation of PBMC at RT for 45 min with
1, 0.1, 0.01 mg ml–1 SHR-1, cells were subjected to the adhesion/tem assay
as described in Materials and MethodsPBMC–endothelial cell interactions, but experiments to relate
MAb concentrations during PBMC preincubation and the extent of
the effects on PBMC adhesion/tem need to be performed.
Recently, Buysmann et al showed that binding of the anti-CD3
MAb OKT3 to T lymphocytes induced a rapid adhesion of
lymphocytes to resting endothelium (Buysmann et al, 1996).
Comparison of both their and our study led us to conclude that
different processes are most likely the basis for the observed
effects. Whereas BIS-1 F(ab¢)2-coated PBMC only started to show
an increased adhesion/tem after 15 min of incubation with
HUVEC (unpublished data), OKT3 pre-incubation of T lympho-
cytes led to a maximum adhesion at 3 min of incubation followed
by a rapid decline (Buysmann et al, 1996). Moreover, we were not
able to block PBMC/BIS-1 F(ab¢)2 induced adhesion with TS1/18
antibody (anti-CD18; kindly provided by Dr N Oppenheimer-
Marks, Dallas, TX, USA). In addition, neither VLA-4 or LFA-
1/L15 neutralizing antibodies were able to specifically inhibit
BIS-1 F(ab¢)2-induced PBMC adhesion/tem (data not shown). Our
observation that preincubation of PBMC with either BIS-1 F(ab¢)2
or BIS-18 both induced VLA-4 and LFA-1 expression on PBMC,
while only BIS-1 F(ab¢)2 binding led to an increase in PBMC–
endothelial cell interaction strengthens the conclusion that the
effects observed with BIS-1 F(ab¢)2 and OKT3 are based on a
different mechanism(s). Possibly, L-selectin is involved in the
effects observed, since L-selectin expression was lost upon BIS-1
F(ab¢)2 binding to PBMC, whereas no L-selectin modulation was
seen upon OKT3 incubation (Buysmann et al, 1996).
The observation that adhesion/tem of BIS-1 F(ab¢)2- and SHR-
1-coated PBMC leads to HUVEC activation is a novel finding.
Recently, two other reports on cell–cell interaction-dependent
endothelial cell activation were published. Sunderkotter et al
found that trinitrochlorbenzene sensitized mouse T-cells were
capable of inducing expression of E-selectin on microvascular
endothelial cells after 4 h of co-culture. The mechanism by which
such an activation occurred is unknown (Sunderkotter et al, 1996).
Furthermore, Lou et al reported that stimulated T-cells were
capable of activating endothelial cells upon direct cell contact.
Membrane-associated TNF-a was partly responsible for this effect
(Lou et al, 1996), but seems unlikely to be responsible for
BsMAb/PBMC-induced HUVEC activation.
The data presented indicate the existence of lymphocyte–
endothelial cell activation pathways of which the responsible
molecular mechanism(s) remain(s) unclear. The fact is that BIS-1
F(ab¢)2 and SHR-1 binding to PBMC induces increased PBMC
adhesion to resting endothelium which may (partly) explain the
paradox of rapid lymphopenia in patients after start of BsMAb
infusion without measurable TNF-a levels. Yet, extrapolation of
these results to the clinical situation is difficult. In this study we
have focused on resting PBMC, as the phenotype of PBMC of IL-
2-treated patients at the start of BIS-1 F(ab¢)2 infusion is similar to
that of the resting PBMC used with respect to the expression of L-
selectin, VLA-4 and LFA-1 (G Molema, unpublished results). We
also performed experiments with in vitro IL-2 and anti-CD3/IL-2-
activated PBMC. The effects observed with BIS-1 F(ab¢)2-coated
activated PBMC were similar to the effects seen with resting
PBMC, although the extent of induction of adhesion/tem differed
between PBMC populations (see Figure 2).
In a rat model of pulmonary metastases, we recently showed
that treatment with a combination of rat IL-2 and rat CD3 ´ EGP-
2-directed BsMAb induced a generalized leucocyte migration into
kidney, liver and lung parenchyma. This effect coincided with an
increased endothelial VCAM-1 expression in these organs. As a
selective antibody for rat E-selectin is not available, E-selectin
expression could not be immunohistochemically analysed yet.
Furthermore, PBMC isolated from IL-2-treated cancer patients
exerted an increased adhesion/tem in vitro when pre-incubated
with BIS-1 F(ab¢)2 (G Molema, unpublished data). These data indi-
cate that in vivo activated leucocytes do respond to CD3-directed
BsMAb in a similar way as described in this study.
Our observations warrant investigations into the occurrence of
effects described in this study in patients receiving i.v. BIS-1
F(ab¢)2, as it may explain the lack of redistribution of effective
amounts of CTL to the solid tumour tissue. Furthermore, compar-
ison of the effects of other CD3-directed MAbs or BsMAbs on
PBMC adhesion/tem may provide a tool to differentiate between
antibodies with respect to their desired therapeutic application.
BsMAbs and newly developed diabodies (Helfrich et al, 1998), are
developed for redirecting cytolytic activity towards tumour cells.
Redistribution of lymphocytes to other sites than the tumour is
therefore undesirable.
The observation that the CD5-directed BsMAb BIS-18 was
devoid of an effect on PBMC adhesion/tem may be exploited for
the development of more selective targeting entities to, e.g. tumour
vasculature-specific antigens (Molema et al, 1997, 1998b). After
distribution to the tumour vascular endothelium, lymphocyte
extravasation towards the tumour cells may be accomplished by
subsequent activation. Furthermore, to redirect the cytolytic
activity against the tumour vascular endothelial cells, selective
redistribution of CTLs by means of a CD5 ´ tumour endothelial
antigen-directed BsMAb may be envisioned without the occur-
rence of a generalized loss of the immunocompetent cells to other
sites in the body.
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